Comparison of ⁶⁸Ga-PSMA PET and mpMRI for prostate cancer local staging: a comprehensive review and direct meta-analysis.

IF 3.5 3区医学 Q2 ONCOLOGY Frontiers in Oncology Pub Date : 2024-11-01 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1410229

Xinyu Jin, Yijie Cai, Xiaolu Ren

{"title":"Comparison of 68Ga-PSMA PET and mpMRI for prostate cancer local staging: a comprehensive review and direct meta-analysis.","authors":"Xinyu Jin, Yijie Cai, Xiaolu Ren","doi":"10.3389/fonc.2024.1410229","DOIUrl":null,"url":null,"abstract":"Purpose: This meta-analysis is conducted to evaluate the comparative diagnostic efficacy of 68Ga-PSMA PET vs. mpMRI in detecting local staging of prostate cancer(PCa).Methods: A comprehensive search was conducted in the PubMed and Embase databases to identify publications up to February 2024. The analysis included studies that evaluated the direct comparison of 68Ga-PSMA PET and mpMRI for local staging of prostate cancer. The reliability of the analyzed studies was evaluated using the QUADAS-2 tool.Results: The meta-analysis included 10 articles involving 505 patients, which revealed that both 68Ga-PSMA PET and mpMRI had similar sensitivities and specificities in detecting extracapsular extension(ECE) and seminal vesicle invasion(SVI). The sensitivities for ECE were 0.56 (95% CI: 0.41-0.71) for 68Ga-PSMA PET and 0.57 (95% CI: 0.43-0.71) for mpMRI, and specificities were both 0.84 (68Ga-PSMA PET 95% CI: 0.75-0.91, mpMRI 95% CI: 0.76-0.91).For SVI, sensitivities were 0.57 (95% CI: 0.46-0.68) for 68Ga-PSMA PET and 0.70 (95% CI: 0.60-0.80) for mpMRI, with specificities of 0.92 (95% CI: 0.86-0.96) for 68Ga-PSMA PET and 0.94 (95% CI: 0.89-0.98) for mpMRI. There were no notable variations in sensitivity or specificity between the two methods for detecting ECE and SVI (P = 0.89 and 0.93 for ECE, 0.09 and 0.57 for SVI).Conclusions: This meta-analysis indicates that 68Ga-PSMA PET has similar sensitivity and specificity to mpMRI in local prostate cancer staging. Nevertheless, the limited study sample size calls for further, larger prospective studies to validate these findings.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=522438, identifier CRD42024522438.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1410229"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563965/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1410229","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This meta-analysis is conducted to evaluate the comparative diagnostic efficacy of ⁶⁸Ga-PSMA PET vs. mpMRI in detecting local staging of prostate cancer(PCa).

Methods: A comprehensive search was conducted in the PubMed and Embase databases to identify publications up to February 2024. The analysis included studies that evaluated the direct comparison of ⁶⁸Ga-PSMA PET and mpMRI for local staging of prostate cancer. The reliability of the analyzed studies was evaluated using the QUADAS-2 tool.

Results: The meta-analysis included 10 articles involving 505 patients, which revealed that both ⁶⁸Ga-PSMA PET and mpMRI had similar sensitivities and specificities in detecting extracapsular extension(ECE) and seminal vesicle invasion(SVI). The sensitivities for ECE were 0.56 (95% CI: 0.41-0.71) for ⁶⁸Ga-PSMA PET and 0.57 (95% CI: 0.43-0.71) for mpMRI, and specificities were both 0.84 (⁶⁸Ga-PSMA PET 95% CI: 0.75-0.91, mpMRI 95% CI: 0.76-0.91).For SVI, sensitivities were 0.57 (95% CI: 0.46-0.68) for ⁶⁸Ga-PSMA PET and 0.70 (95% CI: 0.60-0.80) for mpMRI, with specificities of 0.92 (95% CI: 0.86-0.96) for ⁶⁸Ga-PSMA PET and 0.94 (95% CI: 0.89-0.98) for mpMRI. There were no notable variations in sensitivity or specificity between the two methods for detecting ECE and SVI (P = 0.89 and 0.93 for ECE, 0.09 and 0.57 for SVI).

Conclusions: This meta-analysis indicates that ⁶⁸Ga-PSMA PET has similar sensitivity and specificity to mpMRI in local prostate cancer staging. Nevertheless, the limited study sample size calls for further, larger prospective studies to validate these findings.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=522438, identifier CRD42024522438.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

68Ga-PSMA PET 与 mpMRI 在前列腺癌局部分期方面的比较：全面综述和直接荟萃分析。

目的：本荟萃分析旨在评估68Ga-PSMA PET与mpMRI在检测前列腺癌（PCa）局部分期方面的诊断效果比较：方法：在PubMed和Embase数据库中进行了全面检索，以确定截至2024年2月的出版物。分析包括对 68Ga-PSMA PET 和 mpMRI 用于前列腺癌局部分期的直接比较进行评估的研究。使用QUADAS-2工具评估了所分析研究的可靠性：荟萃分析包括10篇文章，涉及505名患者，结果显示68Ga-PSMA PET和mpMRI在检测囊外扩展（ECE）和精囊侵犯（SVI）方面具有相似的敏感性和特异性。68Ga-PSMA PET 对 ECE 的敏感性为 0.56（95% CI：0.41-0.71），mpMRI 为 0.57（95% CI：0.43-0.71），特异性均为 0.84（68Ga-PSMA PET 95% CI：0.75-0.91，mpMRI 95% CI：0.76-0.91）。对于 SVI，68Ga-PSMA PET 的灵敏度为 0.57（95% CI：0.46-0.68），mpMRI 为 0.70（95% CI：0.60-0.80），68Ga-PSMA PET 的特异性为 0.92（95% CI：0.86-0.96），mpMRI 为 0.94（95% CI：0.89-0.98）。两种方法在检测 ECE 和 SVI 的敏感性和特异性方面没有明显差异（ECE 的 P = 0.89 和 0.93，SVI 的 P = 0.09 和 0.57）：这项荟萃分析表明，68Ga-PSMA PET 与 mpMRI 在前列腺癌局部分期方面具有相似的敏感性和特异性。尽管如此，由于研究样本量有限，需要进一步开展更大规模的前瞻性研究来验证这些发现。系统综述注册：https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=522438，标识符为 CRD42024522438。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.